At SEB’s Nordic Seminar, Bactiguard’s CEO, Christine Lind, presented its technology and provided an update on the strategy to secure growth. We again received the message that there is better stability on the cost side (EBITDA has been positive for six consecutive quarters) and that it is a key priority to secure deals in the therapeutic areas it is focusing on. We believe success there is crucial to the case ahead and for reaching its financial targets.
LÄS MER
